Additionally, it is important to acknowledge the evolving landscape of breast cancer therapeutics, notably, the emergence of HER2-low breast cancer defined as a score of 1+ on IHC analysis or as an IHC score of 2+ and negative results on in situ hybridization [31,32,33]. This evidence concerns the gene ERBB2 and breast cancer.